Grifols has launched a new study into methods of treatment for Alzheimer’s disease.
Newer hydroxyethyl starch (HES) products with molecular weight of 130kDa and substitution ratios ranging from 0.38 to 0.45 (130/0.38-0.45) have been claimed to be safer than higher molecular weight (200/0.5-0.6) HES products, which were shown to cause acute kidney injury in two randomized trials in patients with sepsis.
The U.S. Food and Drug Administration has instructed manufacturers to add information to the current boxed warning in the labeling of all intravenous immune globulin (IVIG) products, and add a similar standardized boxed warning for all subcutaneous and intramuscular IG products.
A computer model for predicting flu outbreaks weeks in advance has been developed by researchers at Columbia University and the National Center for Atmospheric Research.
The U.S. Food and Drug Administration (FDA) has determined that hydroxyethyl starch (HES) solutions should not be used in critically ill adult patients, including patients with sepsis and those admitted to the intensive care unit (ICU).
The U.S. Food and Drug Administration(FDA) has approved an expanded indication for CSL Behring’s Corifact, factor XIII (FXIII) concentrate (human) to include the perioperative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency.
With the objective of evaluating the safety and tolerability of intravenous immune globulin (IVIG) as a treatment for neuromyelitis optica (NMO), a team of Spanish investigators administered IVIG (0.7 g/kg body weight for three days) every two months to eight patients meeting Wingerchuk’s revised diagnostic criteria for the disorder.
Initial results from a Phase 1 trial of the world’s first HIV vaccine has shown no adverse effects while significantly boosting immunity.
A new study published in Hepatology finds that the prevalence of chronic hepatitis B virus (HBV) infection in the U.S. may be as high as 2.2 million cases.
Researchers from Braasch Biotech in South Dakota have developed an obesity vaccine that stimulates the immune system to attack a hormone that promotes slow metabolism and weight gain.
A desensitization protocol using intravenous immune globulin (IVIG) and rituximab has been used for a number of years to allow renal transplantation in highly sensitized (HS) patients, defined as having panel reactive antibody (PRA) >80 percent.
Results from a new study in patients with early Alzheimer’s disease showed a short course of intravenous immune globulin slows the disease’s progression.
